Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19
Status:
Completed
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has
significant anti-inflammatory and antioxidant properties and it lacks of side-effects. This
randomized controlled trial seeks to evaluate the efficacy of intravenous melatonin in
reducing mortality in Covid-19 patients in the ICUs.
Phase:
Phase 2
Details
Lead Sponsor:
Pharmamel S.L.
Collaborators:
Hospital Universitario La Paz Instituto de Investigación Hospital Universitario La Paz